Roche introduces self-testing device for coagulation monitoring
Roche is planning to make its new CoaguChek Vantus system, the first self-testing device for coagulation monitoring with built in Bluetooth technology, commercially available this summer.
With the new system, patients will be able to use their tablet or smartphone with a compatible app to send their results automatically via wireless connectivity, which enables healthcare providers to receive patient INR results rapidly and accurately, while also reducing visits to the lab.
"As healthcare systems face continued pressure to deliver improved access to care at a lower cost, increased connectivity between healthcare providers and patients becomes even more important," said Alan Wright, chief medical officer, Roche Diagnostics. "This innovative technology sets the standard in coagulation monitoring by providing high quality, convenient testing, while optimizing the patient result reporting workflow.
Self-testing can enable patients to test more conveniently, which may improve their time in the target INR range set by their doctor as compared with in-office or lab testing. And when compared with lab testing, patient self-testing has been correlated with fewer thromboembolic events.
Self-testing provides patients with the tools and flexibility to be more engaged in their therapy and this supports better compliance. In addition, self-testing can also help patients stay connected to their doctor, who can quickly receive the results following the patient's self-test.
With the new system, patients will be able to use their tablet or smartphone with a compatible app to send their results automatically via wireless connectivity, which enables healthcare providers to receive patient INR results rapidly and accurately, while also reducing visits to the lab.
"As healthcare systems face continued pressure to deliver improved access to care at a lower cost, increased connectivity between healthcare providers and patients becomes even more important," said Alan Wright, chief medical officer, Roche Diagnostics. "This innovative technology sets the standard in coagulation monitoring by providing high quality, convenient testing, while optimizing the patient result reporting workflow.
Self-testing can enable patients to test more conveniently, which may improve their time in the target INR range set by their doctor as compared with in-office or lab testing. And when compared with lab testing, patient self-testing has been correlated with fewer thromboembolic events.
Self-testing provides patients with the tools and flexibility to be more engaged in their therapy and this supports better compliance. In addition, self-testing can also help patients stay connected to their doctor, who can quickly receive the results following the patient's self-test.